International journal of oncology最新文献_第4页

RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review). RAD51和PALB2在精确肿瘤学：HRD相关乳腺癌和卵巢癌的临床意义（综述）。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-04 DOI: 10.3892/ijo.2025.5771

Mohd Adnan Kausar, Khalid Farhan Alshammari, Fahaad Alenazi, Sadaf Anwar, Amany Mohammed Khalifa, Tarig Ginawi, Abdulaziz Asiri, Mohammad Zeeshan Najm, Syed Arman Rabbani, Mohamed El-Tanani, Saumyatika Gantayat

{"title":"RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review).","authors":"Mohd Adnan Kausar, Khalid Farhan Alshammari, Fahaad Alenazi, Sadaf Anwar, Amany Mohammed Khalifa, Tarig Ginawi, Abdulaziz Asiri, Mohammad Zeeshan Najm, Syed Arman Rabbani, Mohamed El-Tanani, Saumyatika Gantayat","doi":"10.3892/ijo.2025.5771","DOIUrl":"10.3892/ijo.2025.5771","url":null,"abstract":"Maintaining genomic stability is essential for reducing the risk of carcinogenesis. Homologous recombination (HR) is a high‑fidelity DNA repair mechanism that addresses double‑strand breaks and interstrand crosslinks. The present review examined two key components of HR: RAD51, the eukaryotic recombinase and PALB2, a scaffolding protein. Their structural and functional roles are explored in the context of breast and ovarian cancer. RAD51 facilitates homology search and strand invasion, while PALB2 links BRCA1 and BRCA2, stabilizing RAD51 filaments. Mutations in these genes compromise HR, increasing susceptibility to various cancers and impacting treatment efficacy by impairing DNA repair. The present review discussed the clinical implications of RAD51 and PALB2 mutations, focusing on risk stratification, PARP inhibitor efficacy and emerging therapies. Additionally, it highlighted the potential of RAD51 and PALB2 as biomarkers and therapeutic targets, contributing to advances in personalized cancer management.","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Retracted] N6‑methyladenosine upregulates miR‑181d‑5p in exosomes derived from cancer‑associated fibroblasts to inhibit 5‑FU sensitivity by targeting NCALD in colorectal cancer. [引自]N6 -甲基腺苷上调来自癌症相关成纤维细胞的外泌体中的miR - 181d - 5p，通过靶向结直肠癌中的NCALD抑制5 - FU敏感性。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-06-27 DOI: 10.3892/ijo.2025.5768

Shengli Pan, Yingying Deng, Jun Fu, Yuhao Zhang, Zhijin Zhang, Xianju Qin

引用次数: 0

[Corrigendum] Metastasis suppressor 1 expression in human ovarian cancer: The impact on cellular migration and metastasis. 转移抑制因子1在人卵巢癌中的表达：对细胞迁移和转移的影响。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-04 DOI: 10.3892/ijo.2025.5770

Rong Liu, Tracey A Martin, Nicola J Jordan, Fiona Ruge, Lin Ye, Wen G Jiang

{"title":"[Corrigendum] Metastasis suppressor 1 expression in human ovarian cancer: The impact on cellular migration and metastasis.","authors":"Rong Liu, Tracey A Martin, Nicola J Jordan, Fiona Ruge, Lin Ye, Wen G Jiang","doi":"10.3892/ijo.2025.5770","DOIUrl":"10.3892/ijo.2025.5770","url":null,"abstract":"Subsequently to the publication of the above article, an interested reader drew to the authors' attention that, concerning the cell invasion assays shown in Fig. 5A on p. 1436, the 'WT' and 'pEF6' data panels contained apparently overlapping sections of data, such that these experiments were apparently derived from the same original source where the results of differently performed experiments were intended to have been portrayed. After re‑examining their original data, the authors have realized that the data panel in Fig. 5A for the 'pEF6' experiment was inadvertently selected incorrectly. The revised version of Fig. 5, showing all the correct data for Fig. 5A, is shown on the next page. The authors are grateful to the Editor of International Journal of Oncology for allowing them this opportunity to publish a Corrigendum, and all the authors agree with its publication. Furthermore, the authors apologize to the readership for any inconvenience caused. [International Journal of Oncology 47: 1429‑1439, 2015; DOI: 10.3892/ijo.2015.3121].","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12270387/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Corrigendum] Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors. [勘误]蛋白酪氨酸磷酸酶kappa在促血管生成因子诱导的血管生成协调中的双重作用。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-11 DOI: 10.3892/ijo.2025.5772

Ping-Hui Sun, Gang Chen, Malcolm Mason, Wen G Jiang, Lin Ye

引用次数: 0

Novel non‑metal‑based contrast agents for MR imaging: Emerging approaches and clinical perspectives (Review). 新型非金属造影剂用于磁共振成像：新方法和临床观点（综述）。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-19 DOI: 10.3892/ijo.2025.5776

Taoming Du, Haiyang Luo, Huizhen Song, Tao Lin, Qin Yu

{"title":"Novel non‑metal‑based contrast agents for MR imaging: Emerging approaches and clinical perspectives (Review).","authors":"Taoming Du, Haiyang Luo, Huizhen Song, Tao Lin, Qin Yu","doi":"10.3892/ijo.2025.5776","DOIUrl":"10.3892/ijo.2025.5776","url":null,"abstract":"Magnetic Resonance Imaging (MRI) relies on contrast agents to enhance image quality and diagnostic accuracy. Traditional metal‑based agents, such as gadolinium compounds, raise safety concerns due to potential toxicity and long‑term retention in the body. The present review examines recent advancements in non‑metal‑based MRI contrast agents, focusing on fluorine‑19 (19F) compounds, chemical exchange saturation transfer (CEST) agents, nitroxide radicals, and hyperpolarized carbon agents. It discussed the mechanisms by which these agents improve contrast, including their biocompatibility and ability to provide molecular and metabolic information. Key findings highlight the high specificity of19F agents due to negligible background signals, the capacity of CEST agents for molecular imaging without metals, nitroxide radicals' utility in redox‑sensitive imaging, and hyperpolarized 13C compounds' role in real‑time metabolic assessment. Despite challenges such as low sensitivity and technical complexities, these non‑metal‑based agents offer promising, safer alternatives with enhanced diagnostic capabilities, paving the way for more precise and personalized medical imaging.","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274189/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNA‑21: A potential therapeutic target in lung cancer (Review). MicroRNA‑21：肺癌的潜在治疗靶点（综述）

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-11 DOI: 10.3892/ijo.2025.5773

Zhouqiang Li, Hualing Zhang, Zeshan Chen, Guanzhu Wu, Weixing Guo, Yun Li

{"title":"MicroRNA‑21: A potential therapeutic target in lung cancer (Review).","authors":"Zhouqiang Li, Hualing Zhang, Zeshan Chen, Guanzhu Wu, Weixing Guo, Yun Li","doi":"10.3892/ijo.2025.5773","DOIUrl":"10.3892/ijo.2025.5773","url":null,"abstract":"In this review, the role of microRNA‑21 (miRNA‑21) as an oncogene in lung cancer was investigated. Studies have shown that miRNA‑21 can promote the progression of lung cancer by targeting downstream target genes, and its expression can be modulated by transcription factors, DNA methylation or competitive endogenous RNA as an upstream regulator. This review highlights that miRNA‑21 can promote the progression of lung cancer through multiple signaling pathways, with a focus on the PI3K/AKT, MEK/ERK, TGF‑β/SMAD, Hippo, NF‑κB and STAT3 signaling pathways. Mechanistically, miRNA‑21 plays an important role in the progression of lung cancer by regulating multiple biological processes, such as proliferation, invasion, metastasis, apoptosis and angiogenesis in lung cancer cells. Higher expression of miRNA‑21 is associated with chemotherapy, radiotherapy and immune resistance in lung cancer. Targeting these molecular pathways may be a novel therapeutic strategy for treating lung cancer. Additionally, miRNA‑21 can serve as a biomarker for lung cancer diagnosis, prognosis and treatment response. This review also summarized the following: i) Current methods employed to inhibit the expression of miRNA‑21 in lung cancer, including CRISPR/Cas9 technology; ii) the application of natural anticancer agents, oligonucleotides, small molecules and miRNA sponges; and iii) the nano‑delivery systems developed for miRNA‑21 inhibitors. Finally, the advancements in research on miRNA mimics and inhibitors in clinical trials, which may promote the application of miRNA‑21 in clinical trials in lung cancer, were discussed. Given that lung cancer is a considerable public health challenge, these studies provide new ways of treating patients with lung cancer.","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12274176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of abnormal epigenetic regulation of small GTPases in glioma (Review). 小gtpase异常表观遗传调控在胶质瘤中的作用（综述）。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-04 DOI: 10.3892/ijo.2025.5769

Mingyang Zhang, Yimin Huang, Qiang Zhang, Xiaoyan Zhang, Lumei Kang, Jianguo Wang

{"title":"The role of abnormal epigenetic regulation of small GTPases in glioma (Review).","authors":"Mingyang Zhang, Yimin Huang, Qiang Zhang, Xiaoyan Zhang, Lumei Kang, Jianguo Wang","doi":"10.3892/ijo.2025.5769","DOIUrl":"10.3892/ijo.2025.5769","url":null,"abstract":"Brain tumors are one of the most severe types of malignant tumors and glioma accounts for ~80% of malignant brain tumors. The current treatment methods for glioma are limited and patients with glioma often experience relapse following treatment, which leads to a poor prognosis for these patients. Therefore, novel therapeutic targets and methods urgently need to be explored. The present review screened studies that mainly focused on the epigenetic regulation of small guanosine triphosphate (GTP)ase in glioma. These small GTPases participate in most cellular biological processes, including differentiation, proliferation, cell migration, apoptosis, vesicle and organelle dynamics and transport, nuclear dynamics and cytoskeleton regulation. Due to the diversity and importance of the biological functions of small GTPases, an increasing number of studies have focused on them; however, the incidence of changes in the gene structure of small GTPases is considered to be low in glioma. Several studies have shown that the abnormal expression of genes encoding small GTPases is often influenced by epigenetic regulation in glioma. Epigenetic regulation is a dynamic and reversible process, which implies that the reversal of abnormal epigenetic modifications is a potential treatment strategy for glioma. These previous studies, which are summarized in the present review, not only provide new therapeutic targets and prognostic markers, but also provide information regarding the treatment of glioma. The current review may provide valuable insights for future research and promote the clinical translation of relevant research results.","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12272223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of exosomal non‑coding RNAs in cancer‑associated fibroblast‑mediated therapy resistance (Review). 外泌体非编码rna在癌症相关成纤维细胞介导的治疗耐药性中的作用（综述）。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-08-01 Epub Date: 2025-07-19 DOI: 10.3892/ijo.2025.5774

Junxin Li, Yu Huang, Lin Fu, Ming Shi, Gongli Hu, Fei Du, Zhongshu Wang, Yi Xiao, Yan Zhang, Yanyu Li

引用次数: 0

Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model. PD - L1上调对免疫检查点抑制剂在4T1小鼠三阴性乳腺癌中疗效的影响

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-07-01 Epub Date: 2025-06-13 DOI: 10.3892/ijo.2025.5760

A Young Park, Ju Hee Kim, Sangeun Lee, Hoe Suk Kim, Hong Kyu Kim, Han-Byoel Lee, Wonshik Han

{"title":"Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model.","authors":"A Young Park, Ju Hee Kim, Sangeun Lee, Hoe Suk Kim, Hong Kyu Kim, Han-Byoel Lee, Wonshik Han","doi":"10.3892/ijo.2025.5760","DOIUrl":"10.3892/ijo.2025.5760","url":null,"abstract":"Triple‑negative breast cancer (TNBC) is a lethal subtype of breast cancer with a poor prognosis and limited existing treatment options. The immune checkpoint inhibitor, anti‑programmed death ligand 1 (PD‑L1), has recently emerged as a promising alternative in treating TNBC. PD‑L1 is critical in tumor immune evasion and is therefore a key target for cancer immunotherapy. Although anti‑PD‑L1 therapy is effective in breast cancer based on clinical trials, the relationship between PD‑L1 expression levels and treatment response remains unclear. To investigate this, a 4T1 breast cancer cell line that stably overexpressed PD‑L1 was established and was used to create a tumor model in mice. Mice were treated with anti‑PD‑L1 antibodies, and tumor growth was compared between the control and treated groups. PD‑L1 overexpressing tumors did not exhibit an antitumor response to anti‑PD‑L1 therapy compared with the control tumors. Additionally, immune cell infiltration and activation were significantly altered, as shown by immunohistochemical staining and bulk RNA sequencing. In PD‑L1‑overexpressing tumors that did not respond to treatment, immune cell markers and antitumor immune pathways were downregulated. These results demonstrated that excessive PD‑L1 expression creates an immunosuppressive tumor microenvironment, which impairs the efficacy of anti‑PD‑L1 therapy. The present study suggests that excessive PD‑L1 expression reduces the effectiveness of antitumor immunotherapy, and that PD‑L 1 expression levels are essential in predicting the response to antitumor immunotherapy.","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144284316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Retracted] Intestinal trefoil factor activates the PI3K/Akt signaling pathway to protect gastric mucosal epithelium from damage. 【收缩】肠三叶因子激活PI3K/Akt信号通路，保护胃黏膜上皮免受损伤。

IF 4.5 3区医学

International journal of oncology Pub Date : 2025-07-01 Epub Date: 2025-06-06 DOI: 10.3892/ijo.2025.5759

Zhaorui Sun, Hongmei Liu, Zhizhou Yang, Danbing Shao, Wei Zhang, Yi Ren, Baodi Sun, Jinfeng Lin, Min Xu, Shinan Nie

{"title":"[Retracted] Intestinal trefoil factor activates the PI3K/Akt signaling pathway to protect gastric mucosal epithelium from damage.","authors":"Zhaorui Sun, Hongmei Liu, Zhizhou Yang, Danbing Shao, Wei Zhang, Yi Ren, Baodi Sun, Jinfeng Lin, Min Xu, Shinan Nie","doi":"10.3892/ijo.2025.5759","DOIUrl":"10.3892/ijo.2025.5759","url":null,"abstract":"Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that, for the Transwell migration assay experiments shown in Fig. 1C and 3C, three sets of data panels were found to contain overlapping sections of data (including four panels across the figure parts that contained the same overlapping data). A further pair of overlapping data panels were identified for the immunofluorescence experiments shown in Fig. 5. Upon receiving notification of this issue, the authors requested a corrigendum and submitted corrected versions of Figs. 1, 3 and 5. However, upon performing an independent analysis of the data in this paper in the Editorial Office, it was also noted that certain of the data in these figures had appeared subsequently in a pair of more recent publications by the same research group, and moreover, one of these images had been incorporated into one of the three revised figures submitted for the corrigendum. Owing to the large number of duplications of data identified in the published paper, and the apparent mislabelling of the authors' own data files, the Editor of International Journal of Oncology has decided that it should be retracted from the Journal on account of a lack of confidence in the presented data. After contacting the authors, they accepted the decision to retract the paper. The Editor apologizes to the readership for any inconvenience caused. [International Journal of Oncology 45: 1123-1132, 2014; DOI: 10.3892/ijo.2014.2527].","PeriodicalId":14175,"journal":{"name":"International journal of oncology","volume":"67 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12221125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144234038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0